Patients Coming Off Weight-Loss Injections Regain Pounds at a Quadrupled Rate Than Dieters

New research indicates that people who discontinue popular GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass far faster than those who stop traditional diet and exercise plans.

Published data in a major health publication shows that while overweight people can lose substantial amounts of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.

"People buying such drugs must be cognizant of the risk of fast weight regain when the medication concludes," stated researcher Dr. Susan Jebb.

Such speed of recovery implies a return to starting weight within about one and a half years.

Weighing Approaches

The research, which examined dozens of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.

Scientists note that individuals who lose weight through diet and exercise generally experience a less rapid weight regain—around 100 grams monthly—post-intervention.

Understanding the Quick Rebound

Nutrition scientists suggest the way of the jabs explains the accelerated regain.

GLP-1 drugs mimic a body's own chemical called GLP-1, which controls feelings of fullness.

"Artificially providing GLP-1 concentrations several times higher than the body's typical production may cause the system to produce less of its endogenous GLP-1, and could diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.

"Withdrawal of this medication results in hunger is unsuppressed, making overeating a significant risk."

An Ongoing Issue?

Medical guidelines suggest the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.

Many experts argue that, given the high risk of relapse, the therapy is often ongoing.

This view is reinforced by pharmaceutical companies, who say that the findings "highlight the long-term character of obesity," comparing it to managing diseases like hypertension.

User Testimonies

People who have stopped the medication report a intense return of hunger.

"It felt as if a trigger activating and I was suddenly extremely hungry," described a patient.

This challenge is exacerbated if users have not established lasting lifestyle or habit modifications during therapy.

Widespread Interest

Survey data indicate that millions of people in the UK have tried these injections in the last 12 months, with demand continuing to grow.

• Adoption is higher among women compared to men.
• The middle-aged demographic shows the greatest usage rates.
• Many obtain the medications through private healthcare rather than public health services.

Ultimately, clinicians emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a magic cure and maintained weight loss relies on integrated behavioural support.